Article Text

Download PDFPDF
Serum hepcidin level is not an independent surrogate biomarker of disease activity or of radiographic progression in rheumatoid arthritis: results from the ESPOIR cohort

Statistics from


  • Contributors Conception and design of the study, analysis of the results, data interpretation: JS, FB, TS, JC, SK. Hepcidin measurements, analysis of the results, data interpretation: SF, JPB. Statistical analysis: SK, JS, TS, FB. Analysis of the results and data interpretation: FL, MM, OM. All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version. JS and FB had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

  • Funding Grant support was from the French Society of Rheumatology and from Roche Chugai Pharma for serum hepcidin measurement. An unrestricted grant from Merck Sharp and Dohme (MSD) was allocated for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society of Rheumatology, Abbott, Wyeth-Pfizer, Roche also supported the ESPOIR cohort study.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Approval was obtained from Montpellier University Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.